Stocks focused on developing mRNA vaccines, including Moderna (MRNA) and BioNTech (BNTX), are higher in Wednesday trading following a report that an HHS vaccines advisory committee is walking back a possible plan to stop recommending mRNA jabs.
Two individuals with knowledge of the situation told The Washington Post that the Advisory Committee on Immunization Practices has backed off their prior threat.
The two companies developed mRNA COVID-19 vaccines that were widely administered during the pandemic. BioNTech’s shot was developed with Pfizer (PFE).
Several ACIP members had said that DNA elements in the vaccines were potentially harmful.
